trending Market Intelligence /marketintelligence/en/news-insights/trending/if3f46ffnuRTcoRMqca7YQ2 content esgSubNav
In This List

Veloxis Pharmaceuticals appoints chief commercial officer

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Blog

Infographic: The Big Picture 2023 Issuer & Investor Relations Outlook


Veloxis Pharmaceuticals appoints chief commercial officer

Veloxis Pharmaceuticals A/S promoted Mark Hensley to the role of chief commercial officer.

Hensley has been serving as the company's vice president of sales since May 2017. He also held different senior leadership roles in Chiesi USA Inc. and Cornerstone Therapeutics Inc. before joining Veloxis.

Copenhagen-based Veloxis Pharmaceuticals is a specialty pharmaceutical company that develops and commercializes products used in transplant procedures and adjacent therapies.